Quantitative determination method for human serum A beta (amyloid peptide)

Abstract

The invention discloses a quantitative determination method for human serum A beta (Amyloid peptide). The quantitative determination method sequentially comprises the following steps: a) by adopting a kit, preconfiguring a specific rat monoclonal antibody with paved amyloid peptide structure N-terminal amino acid sequence to have capturing immune reaction with amyloid peptide in a plasma sample which is subjected to temperature control and constant-speed centrifugation treatment, to obtain a reaction compound; b) carrying out secondary antigen-antibody reaction to the reaction compound with anti-amyloid peptide specific amino acid sequence rabbit-anti-human amyloid peptide antibody, to obtain a reaction conjugate; c) carrying out color development reaction on the reaction conjugate through a rabbit-anti-rat polyclonal antibody with an enzyme primer, then carrying out quantitative determination through a spectrophotometer. According to the method, the amyloid peptide detection sensitivity can be improved, the sample treatment and operation procedures can be simplified, and the method can provide the laboratory diagnosis for hospital clinical alzheimer disease, disease screening to the crowd carrying dementia genetic history or dementia danger gene, and suspected occult patients, observation / judgment of curative effect of clinical new drugs, and experimental study of universities and colleges.

Description

technical field [0001] The invention relates to a detection method, in particular to a quantitative detection method of human serum Aβ. Background technique [0002] Aβ (Amyloid peptide referred to as Aβ) is a metabolite produced by the hydrolysis of amyloid precursor protein by protease. There are minor background levels in normal brain cells. However, under pathological conditions, including genetic amyloid precursor protein and hydrolase gene mutations, as well as environmental pollution or chemical carcinogens, the increase in Aβ production can lead to an increase in Aβ. Aβ increases and accumulates in the brain to form senile plaques, which eventually destroys the memory function of the brain and leads to dementia or senile dementia. Therefore, Aβ as a biomarker of Alzheimer's disease is currently the only detection method that is devoted to development. [0003] Since Aβ is the key pathogenic factor of Alzheimer's disease and an important symbol that can reflect the...

AI Technical Summary

Problems solved by technology

[0003] Since Aβ is the key pathogenic factor of Alzheimer's disease and an important symbol that can reflect the pathological development process, domestic and foreign countries have been committed to researching effective Aβ detection methods and developing detection kits for many years. At present, the domestic market is basically the introduction of international The existing Aβ detection kits in the market are used for detection. In recent years, the Aβ detection kits sold in the United States have low sensitivity, and the standard range of detection sensitivity is not suitable for the Asian population, and cannot meet the requirements of a small increase in the Aβ level in the early stage of the disease; currently Japan The detection kits sold in the market have high sensitivity, but they are not only very expensive but also require complex sample processing and special detection skills; in addition, the Aβ detection kits sold in the European market are between the United States and Japan, but they have insufficient specificity. The drawbacks of insufficient stability and large detection errors